Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS' kidney rejection drug

The US FDA has approved Bristol-Myers Squibb’s Nulojix to prevent acute rejection in adult patients who have had a kidney transplant

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's (BMS) Nulojix (belatacept), a selective T-cell costimulation blocker, to prevent acute rejection in adult patients who have had a kidney transplant.

The drug is approved for use with other immunosuppressants specifically basiliximab, mycophenolate mofetil and corticosteroids.

"Nulojix is a new option for kidney transplant patients," said Dr Edward Cox, director of office of antimicrobial products in the FDA's Center for Drug Evaluation and Research. 

"This new medication used in combination with other immunosuppressants helps control the immune system and prevents organ rejection in patients receiving kidney transplants."

Results from two controlled Phase III, open-label, randomised, multicentre studies that included more than 1,200 patients and compared two dose regimens of Nulojix with another immunosuppressant, cyclosporine, demonstrated that the recommended Nulojix regimen is safe and effective for the prevention of acute organ rejection.

Nulojix carries a Boxed Warning for an increased risk of developing post-transplant lymphoproliferative disorder (PTLD), a type of cancer where white blood cells grow out of control after an organ transplant. Transplant patients who have never been exposed to Epstein-Barr virus (EBV) have a higher risk of developing PTLD.

Several immunosuppressants, including Nulojix, also carry another Boxed Warning covering the increased risk of serious infections and other cancers.

16th June 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics